Searchable abstracts of presentations at key conferences in endocrinology

ea0038oc5.1 | Thyroid and parathyroid | SFEBES2015

Functional consequences of germline mutations in a novel non-RET medullary thyroid cancer susceptibility gene

Read Martin , Smith Joel , Smith Vicki , Bosseboeuf Emy , Wake Naomi , Watkinson John , Wallis Yvonne , Maher Eamonn , McCabe Christopher , Woodward Emma

Whilst the majority of familial medullary thyroid cancer (MTC) is caused by germline mutations of the RET proto-oncogene, there are families and individuals with predisposition to MTC in whom no RET mutation has been identified (non-RET MTC). Recently, we identified novel mutations in a single gene termed MTC2 in non-RET MTC individuals by whole exome sequencing. The precise role of these MTC2 germline mutations in MTC tumorigenesis is however unclear. Here, we examined the fu...

ea0034p173 | Neoplasia, cancer and late effects | SFEBES2014

The first reported mutations in the pituitary tumor-transforming gene binding factor

Imruetaicharoenchoke Waraporn , Read Martin , Smith Joel , Smith Vicki , Modasia Bhavika , Poole Vikki , Watkins Rachel , Jayne Franklyn , Boelaert Kristien , McCabe Christopher

PBF is a ubiquitous glycoprotein which is over-expressed particularly in endocrine and endocrine-related cancers. Previously classified as a proto-oncogene, 11 substitution-missense mutations of PBF have now been reported in tumours from patients with ovarian, prostate and colorectal cancers via the COSMIC database, suggesting PBF may in fact be an oncogene. We have therefore examined the biological implications of all 11 mutations. Substitution mutations, which occurred acros...